2022 Annual Meeting - Boosting High-risk Prostate Cancer: What Are the Options?
Different practitioners will utilize radiation therapy to treat high risk prostate cancer in different ways and with different modalities. There are a number of approaches that are appropriate in this setting. This proposed session will review the latest evidence on different methods to boost the prostate in high-risk prostate cancer. Options that will be reviewed will include the utilization of LDR or HDR brachytherapy, or SBRT. Quality of life and other considerations of scenarios in which a particular approach would be reasonable will be reviewed as well. We plan to review new data which may indicate novel ways to determine how aggressively to boost a particular patient depending on parameters of their disease and individual patient considerations.
The activity is designed to meet the interests of radiation oncologists, medical oncologists, radiation physicists, nurses and radiation oncology residents.
Upon completion of this activity, participants should be able to:
- Determine which modalities are appropriate to utilize when boosting high-risk prostate cancer.
- Based on patient characteristics, assess which patients require a boost, and which approach is most appropriate for a given clinical scenario.
Israel Deutsch, MD is employed at Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY and has no financial relationships with a commercial interest.
Juanita Crook, MD is employed at University of British Columbia, Kelowna, BC, Canada and receives compensation/remuneration/funding from Abbvie, Ferring, Tersera, Concur Breast Microseed.
Michael Zelefsky, MD is employed at Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY and has no financial relationships with a commercial interest.
Amar Kishan, MD is employed at University of California Los Angeles, Department of Radiation Oncology, Los Angeles, CA and receives compensation/remuneration/funding from ViewRay, Inc., Varian Medical Systems, Inc., Intelligent Automation, Inc.Janssen, Inc.
James Yu, MD is employed at Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY and receives compensation/remuneration/funding from RefleXion, Pfizer, Augmenix/Boston Scientific.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.